Difference between actual and published PK parameters [Study As­sess­ment]

posted by Loky do – Egypt, 2022-02-15 14:20 (356 d 15:45 ago) – Posting: # 22783
Views: 1,174

Thanks Helmut for your reply ;-), excuse my confusion, I have a question regarding dapoxetine biphasic half-life; the initial and terminal half-life (the initial half-life which is 1.3-1.5 hours and the terminal half-life which is 15-19 hours) does this biphasic nature affect the practical obtained half life of the drug? and is this nature could affect the drug variability?

Thanks

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
22 visitors (0 registered, 22 guests [including 10 identified bots]).
Forum time: 06:05 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5